Detroit, Michigan, United States The top activity for fund was in 2019. The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 1 - 5 millions dollars.
The standard case for the fund is to invest in rounds with 6 partakers. Despite the Woodward Angels, startups are often financed by Scott Garber, IrishAngels. The meaningful sponsors for the fund in investment in the same round are RBI Opportunities Fund, Michigan Angel Fund, Kalamazoo Angels.
Among the most popular portfolio startups of the fund, we may highlight Ocuphire Pharma. Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Biopharma.
Funds with similar focus
| Fund Name | Location |
| ChiNext Qianhai Capital | - |
| Dutch Good Growth Fund | - |
| East Seattle Partners | - |
| ERBAN | Kayseri, Kayseri, Turkey |
| ESB International | County Dublin, Dublin, Ireland |
| Fluid Vehicle Owners | - |
| Fuji Electronics | Japan, Tokyo |
| Harvard University | Cambridge, Massachusetts, United States |
| Huarui Tianxin Touzi | Beijing, China, Haidian |
| INNOventure | Kraków, Malopolskie, Poland |
| Leyi Venture Capital | China, Shanghai |
| Mindshift Capital | Dubai, United Arab Emirates |
| Rio Ventures | - |
| STIHL Digital | Baden-Wurttemberg, Germany, Waiblingen |
| Taiwan Sugar Corporation | - |
| Volvo Cars Group | Göteborg, Sweden, Vastra Gotaland |
| Wharton Angel Network | New York, New York, United States |
| Youngy Investment Management Group Co. | China, Guangdong, Guangzhou |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $2M | 23 Feb 2021 | Michigan, United States | |||
Ash & Erie | $1M | 06 Nov 2019 | Detroit, Michigan, United States | ||
Ocuphire Pharma | $5M | 22 Jul 2019 | Michigan, United States |
– Asalyxa Bio closed a $2m seed financing round to advance its lead program into first-in-human clinical trials.
– The financing was led by Research Bridge Partners, co-led by ID Ventures, and also included Michigan Rise Pre-Seed Fund III, BRCC of Western Michigan University, Ann Arbor Spark, Woodward Angels and other undisclosed investors.
– Proceeds from the financing will be used to advance Asalyxa Bio’s lead development candidate, ASX-100, into first-in-human clinical trials.
– Asalyxa Bio’s drug development programs are based on the company’s proprietary PANTHER technology platform, which enables the targeted delivery of therapeutic compounds directly to neutrophils and other key immune cells.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $2M | 23 Feb 2021 | Michigan, United States | |||
Ash & Erie | $1M | 06 Nov 2019 | Detroit, Michigan, United States | ||
Ocuphire Pharma | $5M | 22 Jul 2019 | Michigan, United States |
